Liven Pharma Statistics
Total Valuation
Liven Pharma has a market cap or net worth of PKR 4.23 billion. The enterprise value is 4.08 billion.
| Market Cap | 4.23B |
| Enterprise Value | 4.08B |
Important Dates
The last earnings date was Wednesday, April 29, 2026.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Liven Pharma has 113.04 million shares outstanding. The number of shares has increased by 172.01% in one year.
| Current Share Class | 113.04M |
| Shares Outstanding | 113.04M |
| Shares Change (YoY) | +172.01% |
| Shares Change (QoQ) | +40.23% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.13% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 42.65 |
| PB Ratio | 5.10 |
| P/TBV Ratio | 5.16 |
| P/FCF Ratio | 22.88 |
| P/OCF Ratio | 19.49 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.81 |
| EV / Sales | 41.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 22.06 |
Financial Position
The company has a current ratio of 3.79, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.79 |
| Quick Ratio | 2.27 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.15 |
| Interest Coverage | -234.57 |
Financial Efficiency
Return on equity (ROE) is -81.35% and return on invested capital (ROIC) is -79.66%.
| Return on Equity (ROE) | -81.35% |
| Return on Assets (ROA) | -33.94% |
| Return on Invested Capital (ROIC) | -79.66% |
| Return on Capital Employed (ROCE) | -59.04% |
| Weighted Average Cost of Capital (WACC) | 3.08% |
| Revenue Per Employee | 2.42M |
| Profits Per Employee | -17.10M |
| Employee Count | 41 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 0.70 |
Taxes
In the past 12 months, Liven Pharma has paid 57.92 million in taxes.
| Income Tax | 57.92M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.59% in the last 52 weeks. The beta is -0.22, so Liven Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.22 |
| 52-Week Price Change | -32.59% |
| 50-Day Moving Average | 35.82 |
| 200-Day Moving Average | 52.40 |
| Relative Strength Index (RSI) | 49.05 |
| Average Volume (20 Days) | 170,403 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Liven Pharma had revenue of PKR 99.11 million and -701.22 million in losses. Loss per share was -7.80.
| Revenue | 99.11M |
| Gross Profit | 8.14M |
| Operating Income | -532.35M |
| Pretax Income | -643.30M |
| Net Income | -701.22M |
| EBITDA | -505.26M |
| EBIT | -532.35M |
| Loss Per Share | -7.80 |
Balance Sheet
The company has 178.80 million in cash and 27.37 million in debt, with a net cash position of 151.43 million or 1.34 per share.
| Cash & Cash Equivalents | 178.80M |
| Total Debt | 27.37M |
| Net Cash | 151.43M |
| Net Cash Per Share | 1.34 |
| Equity (Book Value) | 827.96M |
| Book Value Per Share | 6.28 |
| Working Capital | 225.31M |
Cash Flow
In the last 12 months, operating cash flow was 216.89 million and capital expenditures -32.16 million, giving a free cash flow of 184.72 million.
| Operating Cash Flow | 216.89M |
| Capital Expenditures | -32.16M |
| Depreciation & Amortization | 27.09M |
| Net Borrowing | -8.34M |
| Free Cash Flow | 184.72M |
| FCF Per Share | 1.63 |
Margins
| Gross Margin | 8.21% |
| Operating Margin | -537.14% |
| Pretax Margin | -649.09% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | 186.39% |
Dividends & Yields
Liven Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -172.01% |
| Shareholder Yield | -172.01% |
| Earnings Yield | -16.59% |
| FCF Yield | 4.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |